NIAID DIVISION OF ALLERGY, IMMUNOLOGY&TRANSPLANTATION: IMMUNE MEDIATED DISEASES CLINICAL PRODUCTS CENTER (CPC)

NIAID 过敏、免疫学科

• 批准号: 10379049
• 负责人: ANBU DEVASAHAYAM
• 金额: $ 9.12万
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2022-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10379049
• 关键词: 2019-nCoV; Allergic Disease; Asthma; Autoimmune Diseases; Basic Science; Biological; Cell Transplantation; Clinical; Clinical Research; Clinical Trials; Conduct Clinical Trials; Contracts; Coronavirus; Disease; Food; Funding; Hypersensitivity; Immune; Immunology; Intervention Studies; Investigation; Mediating; National Institute of Allergy and Infectious Disease; Opioid; Organ Transplantation; Pharmacologic Substance; Prevention; Rare Diseases; Research; Schedule; Services; Solid; Tissue Transplantation; Transplantation; infectious disease treatment; programs; vaccine trial

The Clinical Product Center under contract, provides Investigational Product Services for all DAIT-funded and/or sponsored clinical research programs and other NIAID-funded clinical trials as needed. Studies to be supported encompass a broad range of immune-mediated & rare diseases, including: (i) asthma and allergic diseases; (ii) autoimmune disorders; (iii) immune-mediated rejection in solid organ, tissue and cell transplantation; and (iv) (v) Basic Science studies (Opioid Vaccine studies). Additionally, and on an as-needed basis, clinical trials of infectious disease treatment (i.e.SARS-CoV-2), prevention and other vaccine studies. Investigational Products to be studied include schedule I through VI pharmaceutical agents, biologics, foods as study interventions, and other agents.

根据合同，临床产品中心根据需要为所有 DAIT 资助和/或赞助的临床研究项目以及其他 NIAID 资助的临床试验提供研究产品服务。所支持的研究涵盖广泛的免疫介导和罕见疾病，包括： (i) 哮喘和过敏性疾病； (ii) 自身免疫性疾病； (iii)实体器官、组织和细胞移植中免疫介导的排斥反应； (iv) (v) 基础科学研究（阿片类疫苗研究）。此外，根据需要进行传染病治疗（即 SARS-CoV-2）、预防和其他疫苗研究的临床试验。待研究的研究产品包括附表 I 至 VI 药剂、生物制品、作为研究干预措施的食品和其他药剂。